PTPRD and non-small cell lung carcinoma: Among all the NSCLC patients, patients with PTPRD mutations showed a longer median PFS (7.95 vs 4.37 months, HR=0.69, p=0.047, Fig. 2f), with a similar result in ns-NSCLC (9.10 vs 4.33 months, HR=0.62, p=0.0184, Fig. 2g).